📈 Markets & Finance
Live
Ocular Therapeutix vs. Prime Medicine: Which Healthcare Stock Is a Better Buy in 2026?
Written by Pamela Kock for The Motley Fool -> Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a DN…
Nasdaq News — 15 June 2026
Text:
8
0
0
Ocular Therapeutix is transitioning into a major player in the retinal disease market with its lead program, Axpaxli. Prime Medicine is pioneering a
Read Full Story at Nasdaq News → Sources
📈 Markets & Finance
Sam Altman says OpenAI's top token spender uses 100 billion tokens a month — and they're not even the world leader
📈 Markets & Finance
Intel, AMD, Micron shares sink as Broadcom results spark semiconductor sector sell-off
📈 Markets & Finance
This Smart‑Money Legend Won Big on Intel. The Rest of His Portfolio Might Be Even More Revealing
📈 Markets & Finance
A new NJ bill would hand pet owners up to $900 in tax credits — and your state could be next
📈 Markets & Finance
Addressing Investor Transparency, Updates from Euronet Worldwide’s (EEFT) First Analyst Day in a Decade
📈 Markets & Finance
MGM Resorts stock jumps as Barry Diller's People Inc. makes bid to take over the company
